OCX Oncocyte

iMDx to Participate in NYC Investment Conferences September 8 - 11

iMDx to Participate in NYC Investment Conferences September 8 - 11

NASHVILLE, Tenn., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., or iMDx, (Nasdaq: IMDX), today announced participation in investor conferences hosted by both H.C. Wainwright and Lake Street Capital Markets. Information for each can be found below:

Event: H.C. Wainwright 27th Annual Global Investment Conference

Date: September 8 – 9, 2025

Location: In-person at the Lotte New York Palace Hotel and virtual

Format: Company presentation on Monday, September 8 at 5:00 pm ET, and one-on-one meetings

Link to live and replay: 

Event: Lake Street Capital Markets 9th Annual Best Ideas Growth Conference (BIG9)

Date: September 11, 2025

Location: In-person at the Yale Club of New York City

Format: One-on-one meetings



Investors wishing to participate are encouraged to reach out to their H.C. Wainwright or Lake Street sales representatives.

About Insight Molecular Diagnostics, Inc.

Insight Molecular Diagnostics is a pioneering diagnostics technology company whose mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes. Investors may visit  for more information.

GraftAssureCore™, GraftAssureIQ™, GraftAssureDx™, VitaGraft™, GraftAssure™, DetermaIO™, and DetermaCNI™ are trademarks of Insight Molecular Diagnostics Inc.

Investor Contact: 

Doug Farrell 

LifeSci Advisors LLC 



EN
26/08/2025

Underlying

OCXOncocyte

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Oncocyte

 PRESS RELEASE
Free
OCX ONCOCYTE

IMDX Supports AST and ASHI STAR Working Group’s Call for Decentralized...

IMDX Supports AST and ASHI STAR Working Group’s Call for Decentralized Transplant Monitoring American Journal of Transplantation position paper also highlights value of absolute quantification of dd-cfDNA as a diagnostic marker, a key feature of iMDx’s flagship GraftAssureTM family of assays NASHVILLE, Tenn., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (iMDx), today congratulated the STAR working group on its position paper in the American Journal of Transplantation in recognizing the need for decentralized organ health testing in the global tran...

January 13, 2026 1 EN
 PRESS RELEASE
Free
OCX ONCOCYTE

iMDx Announces “JPM Week” and “BTIG Snowbird” Conference Participation

iMDx Announces “JPM Week” and “BTIG Snowbird” Conference Participation NASHVILLE, Tenn., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., or iMDx, (Nasdaq: IMDX), today announced members of its management team will participate in the following investor conferences this winter, which will include hosting meetings around the annual J.P. Morgan Healthcare Conference. LifeSci Advisors 15th Annual Corporate Access Event Date: Monday, January 12thLocation: The Beacon Grand, San Francisco, Calif.Format: One-on-one meetings with management Additional “JPM Week” Investor Mee...

January 7, 2026 1 EN
 PRESS RELEASE
Free
OCX ONCOCYTE

iMDx to Welcome Industry Veteran as Vice President of Medical Affairs ...

iMDx to Welcome Industry Veteran as Vice President of Medical Affairs to Prepare for Commercial Transplant Assay Launch Dr. Nick Ioannou brings decades of academia, industry, and clinical experience in organ transplant, nephrology, cardiology, genetics, and oncology NASHVILLE, Tenn., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), or iMDx, today announced that it has appointed Dr. Nick Ioannou, M.D., MHA, to the position of Vice President, Medical Affairs. Dr. Ioannou is a physician-scientist with more than three decades of highly relevant experienc...

January 6, 2026 1 EN
 PRESS RELEASE
Free
OCX ONCOCYTE

iMDx Prepares for U.S. Commercial Launch of GraftAssureDx as Clinical ...

iMDx Prepares for U.S. Commercial Launch of GraftAssureDx as Clinical Trial Nears Completion GraftAssure™ technology adoption further broadens with 20 global transplant centers engaged by year-end 2025, including first Canadian siteGraftAssureDx™ FDA IVD approval application 95% complete at year-end; expect full submission in coming weeksAccelerating planned UK CE mark and EU IVDR submission to first half 2026, following successful TÜV SÜD ISO 13485 stage 1 & 2 audit completions in Q4 2025Strong engagement from clinical community on GraftAssureCore™ kidney registry with 17 U.S. transplant c...

January 5, 2026 1 EN
 PRESS RELEASE
Free
OCX ONCOCYTE

IMDX Reports Q3 2025 Results and Progress Toward 2026 Commercial Launc...

IMDX Reports Q3 2025 Results and Progress Toward 2026 Commercial Launch On track to submit GraftAssureDx™ for FDA review by year-endOn track for commitment to have 20 transplant centers globally engaged with GraftAssure technology by end of 2025GraftAssure assay’s head-to-head data continue to be favorablePreparing to rapidly expand beyond kidney into heart transplant testing NASHVILLE, Tenn., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., or iMDx, (Nasdaq: IMDX), today published the following letter to shareholders in conjunction with its third quarter results:  ...

November 10, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch